Low-risk Notification Pathway for Medical Devices in Ethiopia

1. Key takeaways

Ethiopia maintains a notification procedure (approval by notification) for low-risk devices: Class I non-IVD devices and Class A IVD devices that appear on the official low-risk list qualify for abbreviated assessment. Two boundaries must be remembered from the outset. First, sterile devices and most measuring devices are excluded from the route regardless of class. Second, what is waived is the exhaustive evaluation, not conformity with the Essential Principles of safety and performance — before the device is placed on the market, it must still comply with those principles in full.

The route rewards preparation discipline more than regulatory creativity. Because the list is closed and the exclusions are explicit, eligibility is determined by three checks — list membership, sterility, measuring function — that can be completed in minutes for any given product. But the abbreviated file still carries real content: quality system evidence, market authorization status elsewhere, and a declaration of conformity are all required, and the product remains subject to post-market variations and re-registration exactly like any other authorized device.

2. Legal basis

3. Expert insights

Insight 1: the legal foundation of the low-risk route is the proportionality principle. Section 9.5 of the general guidelines invokes Article 19(1) of Proclamation No. 1112/2019: the stringency of regulatory evaluation should be proportionate to the product type, its nature, and the potential risk to human health. Class I / Class A represents the lowest risk, and subjecting such products to exhaustive evaluation would consume limited public resources and affect availability — that is the legislative rationale for the route. Understanding this rationale matters in practice, because it explains why the route is framed as a closed list rather than an open self-assessment: proportionality is being exercised by the regulator, not delegated to the applicant.

Insight 2: the abbreviated file comprises eight categories and still covers the quality system and market evidence. Section 6.1 lists: the application form; the device list; the authorization letter and agency agreement; the marketing authorization status in other countries; product information (including packaging and labeling); the quality management system certificate; the free sale certificate or marketing authorization certificate; and the declaration of conformity. Compared with Full Assessment, what shrinks is the technical depth, not the documentary skeleton. A file that omits the QMS certificate or the conformity declaration on the assumption that low risk means light evidence will be returned for incompleteness like any other.

Insight 3: the two exclusion conditions must be checked one by one. Section 3 is explicit that the guideline does not apply to all sterile devices and most measuring devices; Section 9.5 of the general guidelines adds that Class I / A devices supplied in a sterile state and some measuring devices do not qualify for the low-risk route. The decision order should be: check the list first, then whether the device is sterile, then whether it has a measuring function. Each condition is independent, and a device that survives the first check can still be removed by either of the other two.

Insight 4: the low-risk route is equally bound by post-market variations and re-registration. Section 7 provides that low-risk devices are subject to the same post-market variation and re-registration procedures as other authorized devices. Simplified registration does not mean registration once and valid for life. Companies that treat the abbreviated route as a one-time event discover at renewal — or at the first product change — that the same lifecycle obligations apply, and that no reminder system was ever built for them.

Insight 5: the list is closed, and eligibility must be matched item by item. Annex I separately sets out the Class A IVD device list and the Class I non-IVD device list; Annex III gives the device categories; Annex IV gives the submission format. A product that is not on the list cannot claim applicability — this is the fundamental difference between a notification procedure and a self-declaration. The route is an invitation extended by the regulator to named products, not a right asserted by the manufacturer over its own classification of risk.

4. Practical recommendations

1. Verify eligibility in the three-step order: list, then sterility, then measuring function, one condition at a time.
2. Compile the device list in the Annex IV format: with the naming system codes attached.
3. Prepare the QMS certificate and free sale certificate even for the abbreviated file.
4. Prepare the declaration of conformity early: the object of the declaration is the Essential Principles.
5. Set variation and re-registration reminders for low-risk devices: treat them with the same discipline as any other pathway.
6. Check the list version against guideline updates: never argue eligibility from an outdated list.

5. Verification checklist

• □ Product confirmed to be on the Annex I list of EFDA-GDL-092
• □ Product confirmed to be supplied non-sterile
• □ Product confirmed to have no measuring function (or the exception confirmed)
• □ Eight categories of abbreviated documents prepared per Section 6.1
• □ Declaration of conformity issued stating conformity with the Essential Principles
• □ Variation and re-registration reminders established

Regulatory information verified as of October 29, 2026. The scope, exclusions and document items of the low-risk pathway described in this article follow the current text of the first edition of EFDA-GDL-092; when the guideline is revised or the list is updated, the content must be re-verified.

• Ethiopia local resource: GRZAN supports manufacturers from the Chinese mainland and overseas in working with the Ethiopian Food and Drug Authority (EFDA) on marketing authorization (MA) applications, the institutional competency certificate (CoC) and import permit applications, including local agent scheme design and agency agreement review, SRA reliance route justification, UMDN coding and classification determination, technical dossier preparation, and vigilance and post-market surveillance system setup.
• Service capabilities: product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), marketing authorization applications and re-registration, low-risk notification eligibility determination, Essential Principles conformity justification, English-language labeling and instructions-for-use localization, vigilance reporting and field safety corrective action support.
• Contact: hito.lin@grzan.cn; website www.grzan.cn. For EFDA registration pathway and classification strategy support for the Ethiopian market, write to info@grzanglobal.com.